August 2009

Long Development Times Linked to Low Patient Accrual Rates for Cancer Trials

A recent study from Oregon Health and Science University (OHSU) indicates that 40 percent of all cancer trials do not achieve the minimum accrual goals necessary to achieve a statistically significant conclusion. Additionally, it was found that the longer the preparation time required to develop the clinical trial, the harder it was to accrue enough …

Long Development Times Linked to Low Patient Accrual Rates for Cancer Trials Read More »

Men Estimated to be 40 Percent More Likely to Die From Cancer

Overall, men are 40 percent more likely to die from cancer, according to a recent study. Additionally, men are 16 percent more likely to contract cancer in the first place. The study, which was initiated by Cancer Research UK, suggests alarmingly different expectations of cancer survival between men and women.When looking specifically at cancers that …

Men Estimated to be 40 Percent More Likely to Die From Cancer Read More »

Direct Chemo Delivery Shows Signs of Prolonging Patient Survival

Malignant gliomas are an especially difficult type of cancer to treat. Manifesting in the brain or spine, patients diagnosed with this deadly form of cancer have only a 3 percent likelihood of surviving five years or more. Now, a new method for delivering chemotherapy drugs is showing early signs of prolonging survival times among patients …

Direct Chemo Delivery Shows Signs of Prolonging Patient Survival Read More »

Opioid Pain Reliever Approved for Breakthrough Pain in Cancer Patients

 Pain is an infamously difficult cancer symptom to treat. Even when potent pain relievers are used, waves of pain often flare up and break through the effects of the medication. This type of pain is known as breakthrough pain. Now, doctors and patients have a new tool to help combat breakthrough pain. Recently, the U.S. …

Opioid Pain Reliever Approved for Breakthrough Pain in Cancer Patients Read More »

“Trojan Horse” Proves Effective in Lowering Cancer’s Resistance to Chemotherapy

During chemotherapy, it is not uncommon for a tumor to become resistant to treatment over time. This fact has proven to be a major obstacle in cancer treatment and, with few alternatives for treatment, patients with chemo-resistant cancer often experience limited timeframes for survival. In an effort to reduce a cancer’s ability to resist chemotherapy …

“Trojan Horse” Proves Effective in Lowering Cancer’s Resistance to Chemotherapy Read More »